Pl Product Manager - Alexion developed and commercializes Soliris® (eculizumab) and Ultomiris® (ravulizumab) approved complement inhibitor to treat patientswith paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. Alexion is also establishing a premier global metabolic rare disease franchise, which includes Kanuma (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D, and Strensiq (asfotase alfa…